RoundTable Healthcare Partners Facilitates Product Acquisition for Bioniche Pharma
Aloprim Enhances Bioniche’s Product Portfolio and Continues Targeted Acquisition Strategy
LAKE FOREST, IL, April 19, 2007 — RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company Bioniche Pharma Group Limited (“Bioniche Pharma”) has entered into a definitive agreement to acquire Aloprim (allourinol sodium) for Injection, a branded pharmaceutical product, from Nabi Biopharmaceuticals for $3.7 million. Aloprim for Injection is indicated for the management of patients with leukemia, lymphoma, and solid-tumor malignancies who are receiving cancer therapy that cause elevations of serum and urinary uric acid levels.
Bioniche Pharma is a leading developer and manufacturer of injectable generic pharmaceuticals. The Company manufactures over 20 non-branded products and has over 7 new products in development. Bioniche Pharma’s products, which come in both vial and syringe formats, include several grandfathered products and 11 approved ANDA, non-branded products sold in the U.S. and Canadian markets. The Company’s products serve a variety of niche markets and are sold to both the primary care and hospital markets.
“We are pleased to continue executing on our acquisition plan of targeting strategic, niche product acquisitions,” said Jack L. McGinley, a Founding Partner of RoundTable and Chairman of the Board of Bioniche Pharma. “Aloprim is an established, brand-name product and will be a great addition to Bioniche Pharma’s portfolio.”
RoundTable acquired a majority stake in Bioniche Pharma in February 2006, and made additional equity investments in May and December 2006 to support product acquisitions and growth initiatives, and to acquire the equity position of a minority shareholder. Bioniche Pharma continues to actively pursue additional product acquisitions with RoundTable’s support.
RoundTable Healthcare Partners, Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the healthcare industry. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise. The partners of RoundTable have significant experience in managing, operating, acquiring and financing multibillion-dollar diversified healthcare companies. RoundTable currently manages $1.1 billion in capital, including two equity funds totaling $900 million and a subordinated debt fund of $200 million. More information about RoundTable Healthcare Partners and its investments can be found at www.roundtablehp.com.